PM-MIKATI-MEDIA-OFFICE
5.10.2021 12:50:14 CEST | Business Wire | Press release
The Media Office of Lebanon’s Prime Minister Najib Mikati has issued the following statement:
In the context of the recently revealed “Pandora Papers” , it would be important to emphasize the fact that the origin of the wealth of Lebano n’s Prime Minister Najib Mikati is derived from over 20 years of sustained work in the telecom sector, that culminated in 2005, with the listing of the telecom company – (that the Mikati family used to own) – on the main board of the London Stock Exchange ; and its subsequent merger with the Johannesburg-based telecom leader MTN . Therefore, the source of wealth of the Mikati family had been well-scrutinized by the concerned bodies and entities that were piloting the Initial Public Offering (IPO) - thus certifying that the same source of wealth was well-documented, legal, legitimate and audited; and that it derived from the family business’ global activities that preceded the entry of Najib Mikati into politics in Lebanon.
The Monaco property, among other assets around the world, specifically mentioned in the “Papers”, is not the only property owned via a corporate entity. Most family assets and properties fall under the same corporate principle of management and good governance. It is a common and lawful business practice that, in case many family members share the same assets, to organize the ownership via legal entities that offer flexibility as well as corporate, financial and fiscal advantages.
In addition, all the assets and properties belonging to PM Najib Mikati have been duly disclosed to the Constitutional Council in Lebanon, as per the prevailing laws, rules and regulations, since he entered politics.
It is worth highlighting that not all people mentioned in the “Pandora Papers” are necessarily accused of wrongdoings. Also, not all fortunes amassed ought to have necessarily happened at the expense of the common good and needy people.
Regrettably, the underlying logic behind the “Papers” drifted toward transforming most, if not all, of those mentioned into “suspicious” individuals &/or companies, by the mere fact of being listed in there - a logic that goes against the free-market business practices and good governance, in liberal economies, principles that the Mikati family defends.
Since its inception, M1 Group (the Mikati family business) – and all of its subsidiaries around the world – have upheld a separation between public and private. They continue to be fully compliant with global standards; retain world-class auditors; and operate in multiple jurisdictions.
The group respects the right of board members &/or senior executives to run for or hold public office. However, politics &/or public office holders do not influence the group’s guiding principles and business operations; and vice-versa.
At all times, PM Mikati and M1 Group respect the rule of law and abide by it everywhere. All rights reserved.
-Ends-
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005618/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 01:00:00 CEST | Press release
-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP-Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month-PROGRESS pediatric development program continues to evaluate zilurgisertib in children aged 2 to <12 years Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for pe
Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 21:19:00 CEST | Press release
The offtake agreement connects Digital Reef’s 3.3 GW data centre pipeline with environmental assets from more than 30 million hectares of Amazon rainforest across South America, where Oreasoc Agriculture works directly on the ground alongside local communities to develop sustainable economies and safeguard their territories. Xange.com’s digital MRV technology monitors both the data centres and the rainforest. At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where D
NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 15:00:00 CEST | Press release
Planned acquisition strengthens NetApp's position in the rapidly growing AI infrastructure market by bringing differentiated metadata innovation and parallel file architecture designed for AI NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata fr
MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 14:57:00 CEST | Press release
The Group was recognised for the strength of its global institutional ecosystem and its contribution to financial markets innovation and community impact MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity
Croma-Pharma Introduces saypha® volume prime Lidocaine25.9.2026 14:04:00 CEST | Press release
New cross-linked hyaluronic acid filler replaces saypha® volume Lidocaine, offering physicians a more versatile solution for both midface volumization and nasolabial folds Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
